PTK6 Antibody, Biotin conjugated

Code CSB-PA614448LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) PTK6 Polyclonal antibody
Uniprot No.
Target Names
PTK6
Alternative Names
Breast tumor kinase antibody; Breast tumour kinase antibody; Protein tyrosine kinase 6 antibody; Protein-tyrosine kinase 6 antibody; Ptk6 antibody; PTK6_HUMAN antibody; Tyrosine protein kinase BRK antibody; Tyrosine-protein kinase BRK antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Protein-tyrosine kinase 6 protein (1-113AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.; Isoform 2 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins.
Gene References into Functions
  1. Using small molecule inhibitors, findings suggest that the kinase activity of PTK6 does not play a significant role in breast tumorigenesis. PMID: 29879184
  2. These results indicate that plasma-membrane-associated PTK6 phosphorylates Eps8, which promotes cell proliferation, adhesion, and migration PMID: 28214294
  3. Expression of PTK6 in established tumors may maintain the epithelial phenotype, preventing tumor progression. PMID: 26983689
  4. analysis of recombinant PTK6 kinase domain by x-ray crystallography reveals details of its binding to inhibitors PMID: 27993680
  5. The crystal structure of the kinase domain of human PTK6 has been reported. PMID: 27480927
  6. PTK6 mRNA and protein levels were elevated in cervical squamous cell cancer and the elevated cytoplasmic expression of PTK6 was associated with tumor grade and short patient survival. PMID: 27311570
  7. PELP1 interacted with GR to activate Brk expression. PMID: 26825173
  8. PTK6 prolongs S-phase and increases the ability of gemcitabine to cause DNA damage in vitro and in vivo PMID: 26013168
  9. BRK expression in a majority of CC can interact with RTK, augmenting growth and interfering with proliferation inhibitors (SAM68). Therapeutically targeting BRK function (in addition to RTK) should be of benefit for CC treatment. PMID: 25770659
  10. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression PMID: 25241146
  11. Establishment of cross talk between PTK6 and CagA by functional studies may further elucidate the underlying biology of H. pylori-mediated gastric cancer PMID: 25838168
  12. PTK6 is expressed in the normal human mammary gland, but does not appear to be active and may have kinase-independent functions that are distinct from its cancer promoting activities at the membrane. PMID: 25153721
  13. Down-regulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma. PMID: 25377660
  14. PTP1B inhibited BRK by dephosphorylating Tyr-342, but activated SRC by antagonizing PAG-dependent inhibition by CSK. PMID: 25897081
  15. Activating mutations in BRK in breast cancer may disrupt intramolecular interactions that normally maintain BRK in an autoinhibited conformation. PMID: 25940761
  16. This study shows that Brk phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4. PMID: 25733683
  17. Hypoxia-induced PTK6 stabilization and subcellular re-localization to the plasma membrane include increased cell motility and invasion, suggesting PTK6 targeting as a therapeutic approach to reduce hypoxia-regulated metastatic potential. PMID: 25019382
  18. PTK6 regulates cellular migration and invasion in pancreatic cancer via ERK signaling. PTK6 may be a novel therapeutic target for pancreatic cancer. PMID: 24788754
  19. BRK has a role in targeting Dok1 for ubiquitin-mediated proteasomal degradation and in promoting cell proliferation and migration PMID: 24523872
  20. Degradation of Brk involved a calpain-1-mediated proteolytic pathway and indicated an inverse relationship between the level of HER2 expression and calpain-1 activity. PMID: 23707532
  21. Protein tyrosine kinase 6 may have a role in poor prognosis and metastasis of nasopharyngeal carcinoma PMID: 23758975
  22. Highly active PTK6 promoted epithelial-mesenchymal transition by enhancing activation of AKT, thereby stimulating cancer cell migration and metastases in xenograft models of prostate cancer. PMID: 23856248
  23. High PTK6 expression is associated with hypoxia-associated breast cancer progression. PMID: 23928995
  24. an important role for PTP1B as a negative regulator of BRK and IGF-1Rbeta signaling in ovarian cancer cells. PMID: 23814047
  25. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. PMID: 23027128
  26. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. PMID: 23291984
  27. present findings indicated that cytoplasmic PTK6 expression is a potential prognostic factor for survival in LSCC patients. High expression of PTK6 was associated with favorable OS and DFS in LSCC patients PMID: 23497344
  28. These results provide evidence for a novel mechanism demonstrating the oncogenic potential of PTK6 through degradation of c-Cbl, which is an E3 ligase important in down-regulation of oncoproteins. PMID: 23352614
  29. Knockdown of PTK6 enhances apoptosis in HCT116 cells with wild-type p53. PMID: 22989419
  30. breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6), a nonreceptor protein-tyrosine kinase highly expressed in most human breast tumors, interacted with EGFR and sustained ligand-induced EGFR signaling. PMID: 22231447
  31. Brk expression in human breast tumors may contribute to progression by inducing p38-driven pro-survival signaling pathways. PMID: 21923922
  32. results demonstrate that Hsp90 plays an essential role in regulating PTK6 stability and suggest that Hsp90 inhibitors may be useful as therapeutic drugs for PTK6-positive cancers, including breast cancer PMID: 22849407
  33. PTK6 was identified as a transcript that is down-regulated in human esophageal squamous cell carcinoma via epigenetic modification at the PTK6 locus. PMID: 22705009
  34. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. PMID: 22547065
  35. a novel function for PTK6 at the plasma membrane PMID: 22084245
  36. show that as primary human keratinocytes are induced to differentiate in vitro, Brk levels decrease PMID: 21240512
  37. present findings indicate an increase of cytoplasmic Brk expression in non-small cell lung cancer PMID: 21603980
  38. Data suggest that since PTK6 plays an important role in HER receptor signal transduction, its down-regulation might be suitable for future therapy approaches in breast cancer. PMID: 21380407
  39. Alternative transcript-PTK6 is able to negatively regulate growth and modulate PTK6 activity, protein-protein associations and/or subcellular localization. PMID: 21479203
  40. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. PMID: 20929863
  41. Brk antagonizes the transcriptional activity of the transcription factor FoxO family of proteins by inhibiting its nuclear localization. As a result, the cell cycle inhibitor p27, a FoxO target gene, is down-regulated. PMID: 20162673
  42. PTK6 enhances EGFR signaling by inhibition of EGFR down-regulation through phosphorylation of ARAP1 in breast cancer cells. PMID: 20554524
  43. AKT is a direct substrate of PTK6 and AKT tyrosine residues 315 and 326 are phosphorylated by PTK6. PMID: 20606012
  44. PTK6 associates with nuclear and cytoplasmic beta-catenin and inhibits beta-catenin- and T-cell factor (TCF)-mediated transcription. PMID: 20026641
  45. the effect of Sam68 was inhibited in a dose-dependent manner by coexpression of an activated form of the nuclear kinase Sik/BRK that hyperphosphorylated Sam68 PMID: 12482964
  46. The tyrosine kinases Brk/PTK6/Sik, Srm, Frk/Rak/Gtk/Iyk/Bsk, and Src42A/Dsrc41 have a low degree of sequence homology to other known kinases. The exon structure of these kinases, called the Brk family, is highly conserved and distinct. PMID: 12725532
  47. BRK plays a role in differentiation of prostate epithelial cells PMID: 12833144
  48. Study suggests that SH3 interactions will govern phosphorylation of many substrates by BRK. PMID: 14676834
  49. Results describe the solution structure and backbone dynamics of the human protein-tyrosine kinase-6 Src homology 2 (SH2) domain using multidimensional NMR spectroscopy. PMID: 15056653
  50. in breast cancer cells breast tumor kinase (Brk) behaves similarly to a constitutively active Brk mutant (YF-Brk) and associates with tyrosine-phosphorylated proteins in deregulated signaling complexes PMID: 15539407

Show More

Hide All

Subcellular Location
Cytoplasm. Nucleus. Cell projection, ruffle. Membrane. Note=Colocalizes with KHDRBS1, KHDRBS2 or KHDRBS3, within the nucleus. Nuclear localization in epithelial cells of normal prostate but cytoplasmic localization in cancer prostate.
Protein Families
Protein kinase superfamily, Tyr protein kinase family, BRK/PTK6/SIK subfamily
Tissue Specificity
Epithelia-specific. Very high level in colon and high levels in small intestine and prostate, and low levels in some fetal tissues. Not expressed in breast or ovarian tissue but expressed in high percentage of breast and ovarian cancers. Also overexpresse
Database Links

HGNC: 9617

OMIM: 602004

KEGG: hsa:5753

STRING: 9606.ENSP00000217185

UniGene: Hs.51133

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*